Pfizer set to buy-out AFLB sending shares to $35 by Tuesday?

This $.73 Company Has Just Announced The Greatest Medical Discovery Of The 21st Century - Invest Now, And You Could Watch Your Shares Explode 4694%! Watch your $5,000 blossom into $239,726 - your $10,000 soars into $479,452 - and this could all happen even before a high priced buyout by "Big Pharma"... seriously! I'll prove below, why a buyout by Pfizer, Merck or Johnson & Johnson may be virtually guaranteed! Savvy Stock Investor: This is the most important medical advance in 80 years. You'd have to go back to 1928, when Penicillin was discovered, to find something as big or as important! A5 Laboratories (ticker: AFLB) has invented a way to make interferon - one of the most important ingredients in drug therapy - 100 times cheaper and potentially 100 to 1,000 times more effective than any competitor's product. What are interferons? And why are they so important? Interferons are natural body proteins made by your white blood cells. They perform a number of critically important immune functions that fight disease and even cancer cells! Even just a shortage of these important "defenders of life", will make you sick and can even lead to death. This is why interferons are used in so many life-saving drug therapy and represent a $9 billion annual business. And what "Big Pharma" is using right now, is genetically engineered, often toxic, difficult to make, and incredibly expensive. But get this, my number-1 bio tech pick for 2010, and perhaps of all time, A5 Laboratories(AFLB) has just announced an astonishing breakthrough! They were able to create a completely natural, non-toxic, easy to produce and suprisingly inexpensive species-specific interferon that could turn the entire medical world upside down, and capture 100% of the interferon market... That's right, 100%! This has never been done before! Best of all (especially for early shareholders) A5 Laboratories (ticker: AFLB) could sell their superior interferon to virtually every major drug company for 1/7th the price, while potentially posting profit margins in excess of 93%! And with the price coming down so dramatically, thousands more companies may buy it, and thousands of new applications can be found for it. Soon, the interferon market could expand from $9 billion to $12 billion, then to $18 billion, and even to $27 billion! And this market will belong to A5 Laboratories (AFLB). This isn't pie in the sky. Interferon is a proven valuable ingredient already approved and used in hundreds of drug formulations, many of them blockbusters with annual sales in the $billions. A5 Laboratories' natural interferon (ng-INF), for which they have 3 patents pending and world-wide manufacturing rights... Will revolutionize medical treatment, for both humans and animals, around the world. And... Virtually every pharmaceutical company, every biotech firm, and every university research lab will beat a path to A5's door to get their superior interferon at 1/7th the current price! I don't have to tell what that'll mean to early share-holders who accumulate AFLB shares between $.75 and $1.50 now... Why major drug companies could be circling AFLB As We Speak The fastest way to sales in the $billions (and windfall profits for A5 and its shareholders) is to license the ng-INF for use in already established blockbuster drugs. A5 could very well cut a licensing deal with Big Pharmaceutical companies, like Bayer and Pfizer, to make and add ng-INF to their already successful products. Assuming A5's ng-INF makes these drugs far more effective, sales could easily double, as it becomes the drug of choice. Then, A5 will collect a percentage-of-sales royalty on the new formulation. Really? Is that so? Let's think about this... Why would these companies cut a royalty deal with A5 Laboratories, when they've already have top-selling drugs? Well, one reason is they'll pay a lot less for the interferon. But... If they don't, their competition could cut a deal with A5 to add ng-INF, likely making their product so much better, the "loser's" sales could dry up overnight, while the "winner's" sales double to $5 billion or more! And if Teva and Pfizer don't want to play ball, Biogen would love to add A5's ng-INF to its products, which might quadruple its current $1.7 billion annual sales to $6.8, while largely killing sales of Pfizer and Teva! Do you see why A5 Laboratories is my #1 bio tech pick of 2010? It's because one of these giant drug companies almost HAS to buy them out in order to cut out the competition completely! If you do only one thing today, it should be reading the full report on A5 Labratories by SELECTING HERE. Mark my words, AFLB has the single greatest breakthrough in drug technology in my lifetime, and I'm not calling AFLB my top Biotech pick lock of 2010 and beyond!! Do NOT MISS this one Select here to read on   Here's to solid investing, Tim Fields Untapped Wealth IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Untapped Wealth does not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Untapped Wealth or an offer or solicitation to buy or sell any security. A5 Laboratories, (AFLB), the company featured in this issue, appears as paid advertising, paid by Towson Development Ltd. to provide public awareness for AFLB. Towson Development Ltd. has approved and signed off as approved for public dissemination all statements made herein regarding AFLB's history, assets, technologies, current as well as prospective business operations and industry information. Untapped Wealth and Capital Financial Media (CFM) have used outside research and writers using public information to create the advertisement coming from Untapped Wealth about AFLB. Although the information contained in this advertisement is believed to be reliable, Untapped Wealth and CFM makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due diligence on this or any other advertised company. Untapped Wealth is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state se- curity administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. CFM has received and managed a total production budget of $400,000 for this advertising effort and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. Untapped Wealth is paid $3,000 as an editorial fee from CFM and also expects to receive new subscriber revenue as a result of this advertising effort. *More information can be received from A5 Laboratories's investor relations firm, or at A5 Laboratories's website www.a5labs.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like A5 Laboratories, advice to in- vestors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasd.com. Any investment should be made only after con- sulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, A5 Laboratories notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may af- fect the Company's actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company's ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc.